Document
false--12-31Q220200001637761falseDEP1Y1110003940000.010.016000000060000000191240002723700019124000272370000P3Y0.010.01150000001500000000P20YP1Y400000072520 0001637761 2020-01-01 2020-06-30 0001637761 2020-07-29 0001637761 2019-01-01 2019-06-30 0001637761 2019-04-01 2019-06-30 0001637761 2020-04-01 2020-06-30 0001637761 2019-12-31 0001637761 2020-06-30 0001637761 2019-06-30 0001637761 2018-12-31 0001637761 us-gaap:CommonStockMember 2018-12-31 0001637761 2019-01-01 2019-03-31 0001637761 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001637761 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001637761 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001637761 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001637761 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001637761 us-gaap:CommonStockMember 2019-06-30 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001637761 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001637761 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001637761 us-gaap:CommonStockMember 2019-03-31 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001637761 2019-03-31 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001637761 us-gaap:RetainedEarningsMember 2018-12-31 0001637761 us-gaap:RetainedEarningsMember 2019-06-30 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001637761 us-gaap:RetainedEarningsMember 2019-03-31 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001637761 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001637761 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001637761 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001637761 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001637761 us-gaap:CommonStockMember 2019-12-31 0001637761 2020-01-01 2020-03-31 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001637761 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001637761 us-gaap:CommonStockMember 2020-03-31 0001637761 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001637761 us-gaap:RetainedEarningsMember 2019-12-31 0001637761 us-gaap:CommonStockMember 2020-06-30 0001637761 us-gaap:RetainedEarningsMember 2020-03-31 0001637761 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001637761 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001637761 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001637761 us-gaap:RetainedEarningsMember 2020-06-30 0001637761 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001637761 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001637761 2020-03-31 0001637761 us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-06-30 0001637761 2020-04-27 0001637761 spne:CreditAgreementMember 2015-12-24 0001637761 srt:MinimumMember spne:CreditAgreementMember 2015-12-24 0001637761 us-gaap:RevolvingCreditFacilityMember spne:CreditAgreementMember 2020-06-30 0001637761 spne:CreditAgreement.ContingentInterestRateTwoMember us-gaap:BaseRateMember 2015-12-24 2015-12-24 0001637761 us-gaap:RevolvingCreditFacilityMember spne:CreditAgreementMember 2015-12-24 0001637761 spne:CreditAgreement.ContingentInterestRateTwoMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-12-24 2015-12-24 0001637761 spne:CreditAgreementContingentInterestRateThreeMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-12-24 2015-12-24 0001637761 srt:MinimumMember spne:CreditAgreementMember 2015-12-24 2015-12-24 0001637761 spne:CreditAgreementContingentInterestRateOneMember us-gaap:BaseRateMember 2015-12-24 2015-12-24 0001637761 spne:CreditAgreementContingentInterestRateOneMember us-gaap:LondonInterbankOfferedRateLIBORMember 2015-12-24 2015-12-24 0001637761 spne:CreditAgreementContingentInterestRateThreeMember us-gaap:BaseRateMember 2015-12-24 2015-12-24 0001637761 srt:MaximumMember spne:CreditAgreementMember 2015-12-24 2015-12-24 0001637761 srt:MaximumMember spne:CreditAgreementMember 2015-12-24 0001637761 spne:CreditAgreementMember 2015-12-24 2015-12-24 0001637761 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001637761 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001637761 srt:MinimumMember us-gaap:EquipmentMember 2020-01-01 2020-06-30 0001637761 srt:MaximumMember spne:InstrumentSetsMember 2020-01-01 2020-06-30 0001637761 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-06-30 0001637761 spne:SoftwareandComputerEquipmentMember 2020-06-30 0001637761 us-gaap:LeaseholdImprovementsMember 2020-06-30 0001637761 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2020-01-01 2020-06-30 0001637761 us-gaap:EquipmentMember 2020-06-30 0001637761 srt:MaximumMember us-gaap:EquipmentMember 2020-01-01 2020-06-30 0001637761 us-gaap:ConstructionInProgressMember 2019-12-31 0001637761 spne:InstrumentSetsMember 2019-12-31 0001637761 spne:InstrumentSetsMember 2020-06-30 0001637761 spne:SoftwareandComputerEquipmentMember 2019-12-31 0001637761 us-gaap:ConstructionInProgressMember 2020-06-30 0001637761 us-gaap:EquipmentMember 2019-12-31 0001637761 srt:MinimumMember spne:InstrumentSetsMember 2020-01-01 2020-06-30 0001637761 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001637761 srt:MinimumMember spne:SoftwareandComputerEquipmentMember 2020-01-01 2020-06-30 0001637761 us-gaap:FurnitureAndFixturesMember 2020-06-30 0001637761 srt:MaximumMember spne:SoftwareandComputerEquipmentMember 2020-01-01 2020-06-30 0001637761 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-06-30 0001637761 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2020-01-01 2020-06-30 0001637761 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-12-31 0001637761 us-gaap:TrademarksAndTradeNamesMember 2019-12-31 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-12-31 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-12-31 0001637761 us-gaap:CustomerRelationshipsMember 2019-12-31 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-06-30 0001637761 us-gaap:CustomerRelationshipsMember 2020-01-01 2020-06-30 0001637761 us-gaap:CustomerRelationshipsMember 2020-06-30 0001637761 us-gaap:TrademarksAndTradeNamesMember 2020-06-30 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember 2020-01-01 2020-06-30 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001637761 us-gaap:TechnologyBasedIntangibleAssetsMember us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-04-01 2020-06-30 0001637761 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001637761 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0001637761 spne:RoyaltypaymentMember 2016-09-26 0001637761 spne:MilestonePaymentMember 2016-09-26 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001637761 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001637761 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001637761 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0001637761 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-01 2020-06-30 0001637761 spne:EmployeeStockPurchasePlanMember 2019-04-01 2019-06-30 0001637761 spne:EmployeeStockPurchasePlanMember 2020-04-01 2020-06-30 0001637761 us-gaap:RestrictedStockMember 2020-04-01 2020-06-30 0001637761 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0001637761 spne:RestrictedStockAwardsandPerformanceStockMember 2019-01-01 2019-06-30 0001637761 us-gaap:EmployeeStockMember spne:EmployeeStockPurchasePlanMember 2020-06-30 0001637761 us-gaap:EmployeeStockMember spne:EmployeeStockPurchasePlanMember 2020-01-01 2020-06-30 0001637761 2018-02-01 2018-03-22 0001637761 us-gaap:EmployeeStockMember spne:EmployeeStockPurchasePlanMember 2018-11-02 0001637761 spne:A2018PlanMember 2020-06-30 0001637761 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0001637761 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001637761 2020-01-10 2020-01-10 0001637761 2020-01-10 0001637761 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0001637761 spne:A2015PlanMember 2020-06-30 0001637761 spne:RestrictedStockAwardsandPerformanceStockMember 2020-01-01 2020-06-30 0001637761 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001637761 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0001637761 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001637761 us-gaap:EmployeeStockOptionMember 2020-06-30 0001637761 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0001637761 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001637761 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001637761 spne:RestrictedStockAwardsandPerformanceStockMember 2020-06-30 0001637761 us-gaap:EmployeeStockMember spne:EmployeeStockPurchasePlanMember 2019-01-01 2019-06-30 0001637761 us-gaap:EmployeeStockMember spne:EmployeeStockPurchasePlanMember 2018-12-31 0001637761 us-gaap:RestrictedStockMember 2020-01-01 2020-06-30 0001637761 2020-01-01 0001637761 us-gaap:AccountingStandardsUpdate201602Member 2020-01-01 0001637761 country:US spne:SpinalFusionHardwareMember 2019-04-01 2019-06-30 0001637761 country:US spne:SpinalFusionHardwareMember 2019-01-01 2019-06-30 0001637761 spne:InternationalMember spne:SpinalFusionHardwareMember 2019-04-01 2019-06-30 0001637761 spne:OrthobiologicsMember 2019-04-01 2019-06-30 0001637761 country:US 2019-01-01 2019-06-30 0001637761 spne:InternationalMember 2019-04-01 2019-06-30 0001637761 country:US 2019-04-01 2019-06-30 0001637761 spne:SpinalFusionHardwareMember 2019-04-01 2019-06-30 0001637761 country:US spne:OrthobiologicsMember 2019-01-01 2019-06-30 0001637761 spne:OrthobiologicsMember 2019-01-01 2019-06-30 0001637761 spne:InternationalMember spne:OrthobiologicsMember 2019-04-01 2019-06-30 0001637761 spne:InternationalMember spne:OrthobiologicsMember 2019-01-01 2019-06-30 0001637761 spne:InternationalMember spne:SpinalFusionHardwareMember 2019-01-01 2019-06-30 0001637761 spne:InternationalMember 2019-01-01 2019-06-30 0001637761 country:US spne:OrthobiologicsMember 2019-04-01 2019-06-30 0001637761 spne:SpinalFusionHardwareMember 2019-01-01 2019-06-30 0001637761 spne:InternationalMember spne:OrthobiologicsMember 2020-01-01 2020-06-30 0001637761 spne:OrthobiologicsMember 2020-01-01 2020-06-30 0001637761 country:US spne:SpinalFusionHardwareMember 2020-04-01 2020-06-30 0001637761 country:US spne:OrthobiologicsMember 2020-04-01 2020-06-30 0001637761 country:US spne:OrthobiologicsMember 2020-01-01 2020-06-30 0001637761 country:US 2020-01-01 2020-06-30 0001637761 spne:SpinalFusionHardwareMember 2020-04-01 2020-06-30 0001637761 spne:InternationalMember 2020-01-01 2020-06-30 0001637761 spne:InternationalMember spne:SpinalFusionHardwareMember 2020-04-01 2020-06-30 0001637761 spne:SpinalFusionHardwareMember 2020-01-01 2020-06-30 0001637761 spne:OrthobiologicsMember 2020-04-01 2020-06-30 0001637761 spne:InternationalMember spne:OrthobiologicsMember 2020-04-01 2020-06-30 0001637761 spne:InternationalMember spne:SpinalFusionHardwareMember 2020-01-01 2020-06-30 0001637761 country:US 2020-04-01 2020-06-30 0001637761 spne:InternationalMember 2020-04-01 2020-06-30 0001637761 country:US spne:SpinalFusionHardwareMember 2020-01-01 2020-06-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure spne:product
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549 
FORM 10-Q 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2020
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             
COMMISSION FILE NO. 001-36905
SeaSpine Holdings Corporation
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
Delaware
 
47-3251758
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)
 
(I.R.S. EMPLOYER
IDENTIFICATION NO.)
5770 Armada Drive, Carlsbad, CA 92008
(Address of principal executive offices) (zip code)
REGISTRANT’S TELEPHONE NUMBER, INCLUDING AREA CODE: (760727-8399
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
SPNE
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x   No  o  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and "emerging growth company" in Rule 12b-2 of the Exchange Act.



Large accelerated filer
o
Accelerated filer
x 
 
 
 
 
Non-accelerated filer
o
Smaller reporting company
 
 
 
 
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes    No  ý
The number of shares of the registrant’s common stock, $0.01 par value, outstanding as of July 29, 2020 was 27,521,745.





SEASPINE HOLDINGS CORPORATION
INDEX

 
Page
Number
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 





PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except per share data)
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2020
 
2019
 
2020
 
2019
Total revenue, net
$
28,589

 
$
39,306

 
$
64,700

 
$
75,456

Cost of goods sold
11,659

 
14,317

 
25,471

 
27,896

Gross profit
16,930

 
24,989

 
39,229

 
47,560

Operating expenses:
 
 
 
 
 
 
 
Selling and marketing
17,013

 
19,896

 
37,489

 
38,870

General and administrative
8,845

 
7,712

 
17,399

 
16,046

Research and development
3,974

 
3,587

 
7,869

 
7,099

Intangible amortization
792

 
793

 
1,584

 
1,585

Impairment of intangible assets

 
4,993

 
1,325

 
4,993

Total operating expenses
30,624

 
36,981

 
65,666

 
68,593

Operating loss
(13,694
)
 
(11,992
)
 
(26,437
)
 
(21,033
)
Other income (expense), net
14

 
(25
)
 
241

 
48

Loss before income taxes
(13,680
)
 
(12,017
)
 
(26,196
)
 
(20,985
)
Provision for income taxes
33

 
19

 
68

 
40

Net loss
$
(13,713
)
 
$
(12,036
)
 
$
(26,264
)
 
$
(21,025
)
Net loss per share, basic and diluted
$
(0.50
)
 
$
(0.64
)
 
$
(0.98
)
 
$
(1.11
)
Weighted average shares used to compute basic and diluted net loss per share
27,279

 
18,917

 
26,852

 
18,894


The accompanying notes are an integral part of these condensed consolidated financial statements.

4




SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(In thousands)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2020
 
2019
 
2020
 
2019
Net loss
$
(13,713
)
 
$
(12,036
)
 
$
(26,264
)
 
$
(21,025
)
Other comprehensive (loss) income
 
 
 
 
 
 
 
Foreign currency translation adjustments
142

 
108

 
(22
)
 
(61
)
Unrealized (loss) gain on investments
(89
)
 
3

 
101

 
14

Comprehensive loss
$
(13,660
)
 
$
(11,925
)
 
$
(26,185
)
 
$
(21,072
)
The accompanying notes are an integral part of these condensed consolidated financial statements.



5




SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except par value data)
 
June 30, 2020
 
December 31, 2019
 
 
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
75,346

 
$
20,199

Short-term investments
25,116

 

Trade accounts receivable, net of allowances of $394 and $111
20,836

 
24,902

Inventories, net
50,630

 
47,155

Prepaid expenses and other current assets
1,480

 
3,906

  Total current assets
173,408

 
96,162

Property, plant and equipment, net
27,592

 
25,751

Right of use assets
8,363

 

Intangible assets, net
15,728

 
19,173

Other assets
578

 
632

Total assets
$
225,669

 
$
141,718

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Short-term debt
$
6,173

 
$

Accounts payable, trade
11,295

 
7,448

Accrued compensation
6,008

 
7,879

Accrued commissions
6,363

 
7,843

Contingent consideration liabilities
2,011

 
1,864

Short-term lease liability
2,110

 

Other accrued expenses and current liabilities
4,364

 
5,444

  Total current liabilities
38,324

 
30,478

Long-term lease liability
7,551

 

Other liabilities
95

 
1,480

Total liabilities
45,970

 
31,958

 
 
 
 
Commitments and contingencies

 

Stockholders' equity:
 
 
 
Preferred stock, $0.01 par value; 15,000 authorized; no shares issued and outstanding at June 30, 2020 and December 31, 2019

 

Common stock, $0.01 par value; 60,000 authorized; 27,399 and 19,124 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively
274

 
191

Additional paid-in capital
380,252

 
284,211

Accumulated other comprehensive income
1,513

 
1,434

Accumulated deficit
(202,340
)
 
(176,076
)
Total stockholders' equity
179,699

 
109,760

Total liabilities and stockholders' equity
$
225,669

 
$
141,718


The accompanying notes are an integral part of these condensed consolidated financial statements.



6




SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
 
Six Months Ended June 30,
 
2020
 
2019
OPERATING ACTIVITIES:
 
 
 
Net loss
$
(26,264
)
 
$
(21,025
)
Adjustments to reconcile net loss to net cash used in operating activities:
 
 
 
Depreciation and amortization
5,216

 
5,456

Instrument replacement expense
930

 
986

Impairment of intangible assets
1,325

 
4,993

Impairment of spinal instruments
210

 
30

Provision for excess and obsolete inventories
2,976

 
1,329

Stock-based compensation
4,752

 
3,917

Loss/(gain) from change in fair value of contingent consideration liabilities
84

 
(506
)
Other
(25
)
 
52

Changes in assets and liabilities:
 
 
 
Accounts receivable
4,048

 
(2,787
)
Inventories
(5,587
)
 
(4,716
)
Prepaid expenses and other current assets
2,417

 
682

Other non-current assets
(10
)
 
(2
)
Accounts payable
1,820

 
1,871

Accrued commissions
(1,487
)
 
754

Other accrued expenses and current liabilities
(2,339
)
 
(2,897
)
Other non-current liabilities
(15
)
 
100

Net cash used in operating activities
(11,949
)
 
(11,763
)
INVESTING ACTIVITIES:
 
 
 
Purchases of property and equipment
(4,463
)
 
(4,900
)
Additions to technology assets
(850
)
 

Purchases of short-term investments
(25,007
)
 

Maturities of short-term investments

 
15,000

Net cash (used in) provided by investing activities
(30,320
)
 
10,100

FINANCING ACTIVITIES:
 
 
 
Proceeds from Paycheck Protection Program Loan
7,173

 

Repayments of Paycheck Protection Program Loan
(1,000
)
 

Proceeds from issuance of common stock- employee stock purchase plan
698

 
671

Proceeds from exercise of stock options
948

 
219

Proceeds from issuance of common stock, net of offering costs
91,622

 

Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units
(1,898
)
 
(1,908
)
Payment of contingent consideration liabilities in connection with acquisition of
business
(72
)
 
(56
)
Net cash provided by (used in) financing activities
97,471

 
(1,074
)
Effect of exchange rate changes on cash and cash equivalents
(55
)
 
(33
)
Net change in cash and cash equivalents
55,147

 
(2,770
)
Cash and cash equivalents at beginning of period
20,199

 
24,233

Cash and cash equivalents at end of period
$
75,346

 
$
21,463

Supplemental cash flow information:
 
 
 
Interest paid
$
78

 
$
76

Income taxes paid
$
105

 
$
88

Non-cash investing activities:
 
 
 
Property and equipment in liabilities
$
3,167

 
$
3,604


The accompanying notes are an integral part of these condensed consolidated financial statements.

7




SEASPINE HOLDINGS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(Unaudited)
(In thousands)
 
 Common Stock
 
 Additional
 
 Accumulated Other
 
 
 
Total
 
Number of
 
 
 
 Paid-In
 
Comprehensive
 
Accumulated
 
Stockholders'
 
Shares
 
 Amount
 
 Capital
 
Income
 
Deficit
 
 Equity
Balance December 31, 2019
19,124

 
$
191

 
$
284,211

 
$
1,434

 
$
(176,076
)
 
$
109,760

Net loss

 

 

 


 
(12,551
)
 
(12,551
)
Foreign currency translation adjustment

 

 

 
(164
)
 

 
(164
)
Unrealized gain on short-term investments

 

 

 
190

 

 
190

Restricted stock issued
213

 
2

 

 

 

 
2

Issuance of common stock - public offering
7,820

 
78

 
91,544

 

 

 
91,622

Issuance of common stock - exercise of stock options
80

 
1

 
901

 

 

 
902

Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units

 

 
(1,855
)
 

 

 
(1,855
)
Stock-based compensation

 

 
1,983

 

 

 
1,983

Balance March 31, 2020
27,237

 
272

 
376,784

 
1,460

 
(188,627
)
 
189,889

Net loss

 

 

 


 
(13,713
)
 
(13,713
)
Foreign currency translation adjustment

 

 

 
142

 

 
142

Unrealized loss on short-term investments

 

 

 
(89
)
 

 
(89
)
Restricted stock issued
79

 
1

 
(1
)
 

 

 

Issuance of common stock under employee stock purchase plan
78

 
1

 
697

 

 

 
698

Issuance of common stock- exercise of stock options
5

 

 
46

 

 

 
46

Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units

 

 
(43
)
 

 

 
(43
)
Stock-based compensation

 

 
2,769

 

 

 
2,769

Balance June 30, 2020
27,399

 
$
274

 
$
380,252

 
$
1,513

 
$
(202,340
)
 
$
179,699


8




 
 Common Stock
 
 Additional
 
 Accumulated Other
 
 
 
Total
 
Number of
 
 
 
 Paid-In
 
Comprehensive
 
Accumulated
 
Stockholders'
 
Shares
 
 Amount
 
 Capital
 
Income
 
Deficit
 
 Equity
Balance December 31, 2018
18,669

 
$
187

 
$
277,096

 
$
1,602

 
$
(136,800
)
 
$
142,085

Net loss

 

 

 

 
(8,989
)
 
(8,989
)
Foreign currency translation adjustment

 

 

 
(169
)
 

 
(169
)
Unrealized gain on short-term investments

 

 

 
11

 

 
11

Restricted stock issued
216

 
2

 

 

 

 
2

Issuance of common stock- exercise of stock options
11

 

 
143

 

 

 
143

Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units

 

 
(1,851
)
 

 

 
(1,851
)
Stock-based compensation

 

 
1,947

 

 

 
1,947

Balance March 31, 2019
18,896

 
189

 
277,335

 
1,444

 
(145,789
)
 
133,179

Net loss

 

 

 

 
(12,036
)
 
(12,036
)
Foreign currency translation adjustment

 

 

 
108

 

 
108

Unrealized gain on short-term investments

 

 

 
3

 

 
3

Restricted stock issued
71

 
1

 

 

 

 
1

Issuance of common stock under employee stock purchase plan
64

 
1

 
670

 

 

 
671

Issuance of common stock- exercise of stock options
5

 

 
76

 

 

 
76

Repurchases of common stock for income tax withheld upon vesting of restricted stock awards and restricted stock units

 

 
(57
)
 

 

 
(57
)
Stock-based compensation

 

 
1,970

 

 

 
1,970

Balance June 30, 2019
19,036

 
191

 
279,994

 
1,555

 
(157,825
)
 
123,915

The accompanying notes are an integral part of these condensed consolidated financial statements.

9




SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. BUSINESS AND BASIS OF PRESENTATION
Business
SeaSpine Holdings Corporation was incorporated in Delaware on February 12, 2015 in connection with the spin-off of the orthobiologics and spinal implant business of Integra LifeSciences Holdings Corporation, a diversified medical technology company. The spin-off occurred on July 1, 2015. Unless the context indicates otherwise, (i) references to "SeaSpine" or the "Company" refer to SeaSpine Holdings Corporation and its wholly-owned subsidiaries, and (ii) references to "Integra" refer to Integra LifeSciences Holdings Corporation and its subsidiaries other than SeaSpine.
SeaSpine is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implant solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures in the lumbar, thoracic and cervical spine. The Company believes this broad combined portfolio of orthobiologics and spinal implant products is essential to meet the “complete solution” requirements of such surgeons.
Basis of Presentation and Principles of Consolidation
The Company prepared the unaudited interim condensed consolidated financial statements included in this report in accordance with accounting principles generally accepted in the U.S. (GAAP) for interim financial information and the rules and regulations of the Securities and Exchange Commission (SEC) related to quarterly reports on Form 10-Q.
The Company’s financial statements are presented on a consolidated basis. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. Intercompany accounts and transactions have been eliminated in consolidation. The unaudited interim condensed consolidated financial statements do not include all information and disclosures required by GAAP for annual audited financial statements and should be read with the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the SEC. In the opinion of management, the unaudited interim condensed consolidated financial statements included in this report have been prepared on the same basis as the Company's audited consolidated financial statements and include all adjustments (consisting only of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations, cash flows, and statement of equity for periods presented. The results for the three and six months ended June 30, 2020 are not necessarily indicative of the results expected for the full year. In addition, the full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including revenues, expenses, manufacturing, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain and cannot be predicted. See Note 2. Summary of Significant Accounting Policies-Use of Estimates, below. The condensed consolidated balance sheet as of December 31, 2019 was derived from the audited consolidated balance sheet for the year ended December 31, 2019. Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.
Under current SEC rules, generally, a company qualifies as a "smaller reporting company" if it has a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter. If a company qualifies as a smaller reporting company on that date, it may elect to reflect that determination and use the smaller reporting company scaled disclosure accommodations in its subsequent SEC filings until the beginning of the first quarter of the fiscal year following the date it determines it does not qualify as a smaller reporting company. The Company's public float as of June 30, 2020, the last business day of its most recent second fiscal quarter, was less than $250 million, and as such, the Company qualifies as a smaller reporting company, elected to reflect that determination and intends to use certain of the scaled disclosure accommodations in its SEC filings made during and for each of the years ended December 31, 2020 and 2021.
Concentration of Risk
Integra and PcoMed, LLC (PcoMed) entered into a supply agreement in May 2013 (the Supply Agreement), which was subsequently assigned to the Company by Integra in May 2015. For the six months ending June 30, 2020, the sales of products incorporating the NanoMetalene® technology licensed and supplied to the Company pursuant to the Supply Agreement exceeded 10% of the Company's revenue.

10

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Pursuant to the Supply Agreement, PcoMed granted the Company a worldwide exclusive license to sell certain of its products treated with certain proprietary PcoMed technology (Treatment) for use in the spinal interbody and intervertebral market (Treated Products). PcoMed serves as the sole supplier of the Treatment. As consideration for the license and the Treatment, the Company paid to PcoMed initial milestone payments prior to the initial sale and the Company will pay PcoMed a low single digit royalty on the Company’s net sales of all Treated Products. In the event the Company fails to meet any of its payment obligations, the license will, at PcoMed’s option and following a cure period, convert to a non-exclusive license. The Supply Agreement contains customary representations and termination provisions, including for material breach and bankruptcy. Each of the Company and PcoMed retain the rights to their respective intellectual property.
The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash. Cash balances are maintained primarily at major financial institutions in the United States and exceed the regulatory limit of $250,000 insured by the Federal Deposit Insurance Corporation (FDIC). The Company has not experienced any credit losses associated with its cash balances.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
Preparing consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities, and the reported amounts of revenues and expenses. Significant estimates affecting amounts reported or disclosed in the consolidated financial statements include allowances for doubtful accounts receivable and sales returns and other credits, net realizable value of inventories, discount rates and estimated projected cash flows used to value and test impairments of identifiable intangible and long-lived assets, assumptions related to the timing and probability of product launch dates, discount rates matched to the estimated timing of payments, probability of success rates and discount adjustments on the related cash flows for contingent considerations in business combinations, depreciation and amortization periods for identifiable intangible and long-lived assets, computation of taxes, valuation allowances recorded against deferred tax assets, the valuation of stock-based compensation and loss contingencies. These estimates are based on historical experience and on various other assumptions believed to be reasonable under the current circumstances. Actual results could differ from these estimates.
The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations and financial condition, including revenues, expenses, manufacturing, research and development costs and employee-related compensation, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain it or treat COVID-19, as well as the economic impact on local, regional, national and international customers and markets. We have made estimates of the impact of COVID-19 within our financial statements and there may be changes to those estimates in future periods. Actual results may differ from these estimates.
Recent Accounting Standards Not Yet Adopted
The Company qualifies as an “emerging growth company” (EGC) under the Jumpstart Our Business Startups (JOBS) Act and elected to take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, which permits EGCs to defer compliance with new or revised accounting standards until non-issuers must comply with such standards. Accordingly, so long as the Company continues to qualify as an EGC, the Company will not have to adopt or comply with new or revised accounting standards until non-issuers must adopt or comply with such standards. The Company will no longer qualify as an EGC on December 31, 2020, the last day of the fiscal year following the fifth year after its spin-off from Integra.
In June 2016, the FASB issued Accounting Standards Update (ASU or Update) No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires credit losses on most financial assets measured at amortized cost, including trade receivables, and certain other instruments to be measured using an expected credit loss model, referred to as the current expected credit loss model. Under this model, entities will estimate credit losses over the entire contractual term of the instrument. The new standard will be effective for the Company beginning January 1, 2023. The FASB subsequently issued other related ASUs that amend ASU 2016-13 to provide clarification and additional guidance. The Company is evaluating the impact of this standard on its consolidated financial statements.
In August 2018, the FASB issued Update No. 2018-15, Intangibles-Goodwill and Other-Internal Use Software (Subtopic 350-40). The amendments in this Update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The new standard will be

11

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

effective for the Company beginning on January 1, 2021. Early adoption is permitted. The Company is evaluating the impact of this standard on its consolidated financial statements.
In April 2019, the FASB issued Update No. 2019-04, Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. This Update includes several amendments to the FASB Accounting Standards Codification (Codification) intended to clarify, improve, or correct errors therein. Some amendments do not require transition guidance and are effective upon issuance. The amendments requiring transition guidance have the same effective dates as Update No. 2016-13 and will be effective for the Company beginning on January 1, 2023. The Company is evaluating the impact of this standard on its consolidated financial statements.
Recently Adopted Accounting Standards
In February 2016, the FASB issued Update No. 2016-02, Leases (Topic 842). The new standard requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than twelve months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. The new standard must be adopted using the modified retrospective approach. In July 2018, the FASB issued Update No. 2018-10, Codification Improvements to Topic 842 (Leases) and Update No. 2018-11, Leases (Topic 842): Targeted Improvements. In March 2019, the FASB issued Update No. 2019-01, Leases (Topic 842): Codification Improvements. In November 2019, the FASB issued Update No. 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates, which modifies the effective dates for Topic 842. The amendments in ASU 2018-10, ASU 2018-11, ASU 2019-01, and ASU 2019-10 provide additional clarification and implementation guidance on certain aspects of Topic 842 and have the same effective date and transition requirements as ASU 2019-10. The Company early adopted the new standard beginning on January 1, 2020. The Company adopted the new standard electing the optional transition method that allows for a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company applied the transition package of practical expedients allowed by the standard. As a result of the Company’s adoption of the new standard, the Company recorded right-of-use assets and lease liabilities of $9.1 million and $10.5 million, respectively, for existing operating leases in the consolidated balance sheets at January 1, 2020. Additionally, the Company reversed $1.4 million of deferred rent liabilities previously recorded under the previous accounting guidance. The adoption of this new standard had no material impact on its consolidated results of operations or cash flows.
In June 2018, the FASB issued Update No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This Update requires an entity to apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, the period of time over which share-based payment awards vest and the pattern of cost recognition over that period). The amendments specify that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments also clarify that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements.
In August 2018, the FASB issued Update No. 2018-13, Fair Value Measurement (Topic 820)-Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this Update modify the disclosure requirements on fair value measurements in Topic 820 based on the concepts in the Concepts Statement including the consideration of costs and benefits. The new standard was effective for the Company beginning on January 1, 2020. The adoption of this new standard had no material impact on its consolidated financial statements.
In March 2020, the FASB issued Update No. 2020-04, Reference Rate Reform (Topic 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments in this Update apply only to contracts, hedging relationships, and other transactions that reference LIBOR, or another reference rate expected to be discontinued, due to the reference rate reform. The new standard was effective for the Company beginning March 12, 2020. The adoption of this new standard had no material impact on its consolidated financial statements.

12

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Net Loss Per Share
Basic and diluted net loss per share was calculated using the weighted-average number of shares of common stock outstanding during the period. The weighted average number of shares used to compute diluted net loss per share excludes any assumed exercise of stock options, any assumed issuance of common stock under restricted stock awards or units, and any assumed issuances under the Company's employee stock purchase plan, because the effect, in each case, would be antidilutive. Common stock equivalents of 4.3 million and 3.7 million shares for the six months ended June 30, 2020 and 2019, respectively, were excluded from the calculation because of their antidilutive effect.
3. DEBT AND INTEREST
Credit Agreement
In December 2015, the Company entered into a three-year credit facility with Wells Fargo Bank, National Association, which was amended in October 2016 and in July 2018 (the Credit Facility). The Credit Facility provides an asset-backed revolving line of credit of up to $30.0 million with a maturity date of July 27, 2021, which is subject to a one-time, one-year extension at the Company's election. In addition, under the Credit Facility, at any time through July 27, 2020, the Company may increase the $30.0 million borrowing limit by up to an additional $10.0 million, subject to the Company having sufficient amounts of eligible accounts receivable and inventory and to customary conditions precedent, including obtaining the commitment of lenders to provide such additional amount. On July 30, 2020, the Company and Wells Fargo entered into an amendment to the Credit Facility to extend the date through which the Company may elect to increase the borrowing limit under the Credit Facility from July 27, 2020 to July 27, 2021. In connection with entering into the Credit Facility, the Company was required to become a guarantor and to provide a security interest in substantially all its assets for the benefit of the counterparty.
There were no amounts outstanding under the Credit Facility at June 30, 2020 or December 31, 2019. At June 30, 2020, the Company had $20.0 million of current borrowing capacity under the Credit Facility before the requirement to maintain the minimum fixed charge coverage ratio as discussed below. Debt issuance costs and legal fees related to the Credit Facility totaling $0.6 million were recorded as a deferred asset and are being amortized ratably over the term of the arrangement.
Borrowings under the Credit Facility accrue interest at the rate then applicable to base rate loans (as customarily defined), unless and until converted into LIBOR rate loans (as customarily defined) in accordance with the Credit Facility. Borrowings bear interest at a floating annual rate equal to (a) during any month for which the Company's average excess availability (as customarily defined) is greater than $20.0 million, (i) base rate plus 1.25 percentage points for base rate loans and (ii) LIBOR rate plus 2.25 percentage points for LIBOR rate loans, (b) during any month for which the Company's average excess availability is greater than $10.0 million but less than or equal to $20.0 million, (i) base rate plus 1.50 percentage points for base rate loans and (ii) LIBOR rate plus 2.50 percentage points for LIBOR rate loans and (c) during any month for which the Company's average excess availability is less than or equal to $10.0 million, (i) base rate plus 1.75 percentage points for base rate loans and (ii) LIBOR rate plus 2.75 percentage points for LIBOR rate loans. The Company also pays an unused line fee based on the average amount borrowed under the Credit Facility for the most recently completed month. If such average amount is 25% or greater of the maximum borrowing capacity, the unused fee will be equal to 0.375% per annum of the amount unused under the Credit Facility, and if such average amount is less than 25%, the unused line fee will be equal to 0.50% per annum of the amount unused under the Credit Facility. The unused line fee is due on the first day of each month.
The Credit Facility contains various customary affirmative and negative covenants, including prohibiting the Company from incurring indebtedness without the lender’s consent. The Credit Facility also includes a financial covenant that requires the Company to maintain a minimum fixed charge coverage ratio of 1.10 to 1.00 for the applicable measurement period, if the Company's Total Liquidity (as defined in the Credit Facility) is less than $5.0 million. The Company was in compliance with all applicable covenants at June 30, 2020.
The Credit Facility also includes customary events of default, including events of default relating to non-payment of amounts due under the Credit Facility, material inaccuracy of representations and warranties, violation of covenants, bankruptcy and insolvency, failure to comply with health care laws, violation of certain of the Company’s existing agreements, and the occurrence of a change of control. Under the Credit Facility, if an event of default occurs, the lender will have the right to terminate the commitments and accelerate the maturity of any loans outstanding.

13

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Paycheck Protection Program
In April 2020, due to the economic uncertainty resulting from the impact of the COVID-19 pandemic on the Company's operations and to support its ongoing operations and retain all employees, the Company applied for a loan under the Paycheck Protection Program (PPP) of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). The Company received a loan in the original principal amount of $7.2 million. The Company subsequently repaid $1.0 million of the loan. Under the terms of the PPP, subject to specified limitations, the loan may be forgiven if the proceeds are used in accordance with the CARES Act. The Company intends to use the loan proceeds for purposes consistent with the terms of the PPP and intends to apply for forgiveness of the entire loan; however, no assurance is provided that the Company will obtain forgiveness of the loan in whole or in part. Any unforgiven portion of the loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months.
4. INVESTMENTS
The amortized cost, estimated fair value and gross unrealized gains and losses on investments are shown in the table below:
 
June 30, 2020
 
Amortized Cost
 
Gross Unrealized
 
Fair Value
 
 
Gains
 
(Losses)
 
 
(In thousands)
U.S. Treasury Bills
$
25,015

 
$
101

 
$

 
$
25,116


There were no realized gains or losses during the three and six months ended June 30, 2020. As of December 31, 2019, there were no short-term investments.
5. INVENTORIES
Inventories consisted of:

June 30, 2020
 
December 31, 2019
 
(In thousands)
Finished goods
$
35,412

 
$
30,042

Work in process
8,364

 
10,847

Raw materials
6,854

 
6,266

 
$
50,630

 
$
47,155


6. PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment are stated at historical cost less accumulated depreciation and amortization and any impairment charges. The Company provides for depreciation using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the lease term or the useful life. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The cost of computer software obtained for internal use is accounted for in accordance with the Codification 350-40, Internal-Use Software.
The cost of purchased spinal instruments which the Company consigns to hospitals and independent sales agents to support surgeries is initially capitalized as construction in progress. The amount is either then reclassified to spinal instruments and sets, and depreciation is initiated when instruments are put together in a newly built set with spinal implants, or directly expensed for the instruments used to replace damaged instruments in an existing set. The depreciation expense and direct expense for replacement instruments are recorded in selling and marketing expense.

14

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Property, plant and equipment balances and corresponding useful lives were as follows:
 
June 30, 2020
 
December 31, 2019
 
Useful Lives
 
(In thousands)
 
 
Leasehold improvements
$
5,956

 
$
5,878

 
Shorter of lease term or useful life
Machinery and production equipment
9,038

 
8,562

 
 
3
-
10
years
Spinal instruments and sets
29,303

 
25,511

 
 
4
-
5
years
Information systems and hardware
7,778

 
7,442

 
 
3
-
7
years
Furniture and fixtures
1,456

 
1,412

 
 
3
-
5
years
Construction in progress
9,941

 
9,716

 
 
 
 
 
 
     Total
63,472

 
58,521

 
 
 
 
 
 
Less accumulated depreciation and amortization
(35,880
)
 
(32,770
)
 
 
 
 
 
 
Property, plant and equipment, net
$
27,592

 
$
25,751

 
 
 
 
 
 

Depreciation and amortization expenses totaled $1.6 million and $1.2 million for the three months ended June 30, 2020 and 2019, respectively, and $3.1 million and $2.3 million for the six months ended June 30, 2020 and 2019, respectively. The cost of purchased instruments used to replace damaged instruments in existing sets and recorded directly to instrument replacement expense totaled $0.6 million and $0.4 million for the three months ended June 30, 2020 and 2019, respectively, and $0.9 million and $1.0 million for the six months ended June 30, 2020 and 2019, respectively.
For the six months ended June 30, 2020, the Company recorded impairment charges to selling and marketing expense totaling $0.2 million against spinal instruments that are no longer expected to be placed into service. Impairment charges against spinal instruments recorded for the three months ended June 30, 2020 and the three and six months ended June 30, 2019 were immaterial.


15

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

7. IDENTIFIABLE INTANGIBLE ASSETS
Identifiable intangible assets are initially recorded at fair value at the time of acquisition, generally using an income or cost approach. The Company capitalizes costs incurred to renew or extend the term of recognized intangible assets and amortizes those costs over their expected useful lives.
Primarily as a result of an expected shift in future product revenue mix more toward a parallel expanding interbody device designed based on the Company’s internally developed technology and, in turn, lower future revenue anticipated for the lordotic expanding implant based on technology the Company acquired from N.L.T. Spine Ltd. (NLT) and NLT Spine, Inc., a wholly owned subsidiary of NLT, the Company's estimated future net sales associated with those NLT Spine product technologies decreased. Accordingly, the Company evaluated the ongoing value of the product technology intangible assets associated with the acquisition of these assets. Based on this evaluation, the Company determined that intangible assets with a carrying amount of $1.6 million were no longer recoverable and were impaired, and the Company wrote those intangible assets down to their estimated fair value of $0.3 million at March 31, 2020. Significant estimates used in determining the estimated fair value include measurements estimating cash flows and determining the appropriate discount rate, which are considered Level 3 inputs under Codification 820.
The components of the Company’s identifiable intangible assets were:
 
June 30, 2020
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Product technology
12 years
 
$
32,641

 
$
(29,255
)
 
$
3,386

Customer relationships
12 years
 
56,830

 
(44,488
)
 
12,342

Trademarks/brand names
 
300

 
(300
)
 

 
 
 
$
89,771

 
$
(74,043
)
 
$
15,728

 
December 31, 2019
 
Weighted
Average
Life
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Product technology
12 years
 
$
34,158

 
$
(28,912
)
 
$
5,246

Customer relationships
12 years
 
56,830

 
(42,903
)
 
13,927

Trademarks/brand names
 
300

 
(300
)
 

 
 
 
$
91,288

 
$
(72,115
)
 
$
19,173


Annual amortization expense (including amounts reported in cost of goods sold) is expected to be approximately $4.2 million in 2020, $4.1 million in 2021, $4.0 million in 2022, $3.4 million in 2023, and $1.5 million in 2024. For the three months ended June 30, 2020 and 2019, amortization expense totaled $1.0 million and $1.5 million, respectively, and included $0.2 million and $0.7 million, respectively, of amortization of product technology intangible assets that is presented within cost of goods sold. Amortization expense totaled $2.1 million and $3.1 million for the six months ended June 30, 2020 and 2019, respectively, and included $0.5 million and $1.5 million, respectively, of amortization of product technology intangible assets that is presented within cost of goods sold.


16

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

8. FAIR VALUE MEASUREMENTS
The fair values of the Company’s assets and liabilities, including contingent consideration liabilities, are measured at fair value on a recurring basis, and are determined under the fair value categories as follows (in thousands):
 
 
Total
 
Quoted Price in Active Market (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
June 30, 2020:
 
 
 
 
 
 
 
 
Short-term investments
 
$
25,116

 
$
25,116

 
$

 
$

 
 
 
 
 
 
 
 
 
    Contingent consideration liabilities- current
 
$
2,011

 
$

 
$

 
$
2,011

    Contingent consideration liabilities- non-current
 
95

 

 

 
95

Total contingent consideration
 
$
2,106

 
$

 
$

 
$
2,106


 
 
Total
 
Quoted Price in Active Market (Level 1)
 
Significant Other Observable Inputs (Level 2)
 
Significant Unobservable Inputs (Level 3)
December 31, 2019:
 
 
 
 
 
 
 
 
Short-term investments
 
$

 
$

 
$

 
$

 
 
 
 
 
 
 
 
 
    Contingent consideration liabilities- current
 
$
1,864

 
$

 
$

 
$
1,864

    Contingent consideration liabilities- non-current
 
230

 

 

 
230

Total contingent consideration
 
$
2,094

 
$

 
$

 
$
2,094


Short-term investments are classified with Level 1 of the fair value hierarchy because they use quoted market prices in active markets for identical assets.
Under the terms of the 2016 asset purchase agreement between the Company and NLT, the Company is obligated to pay up to a maximum $5.0 million in milestone payments to NLT, payable at the Company's election in cash or in shares of its common stock. Such milestone payments are contingent on the Company's achievement of four independent events related to the commercialization of the product technologies the Company acquired in the transaction. The Company achieved one of the milestones during the three months ended June 30, 2020 and elected to pay the milestone payment at a value of $1.0 million in shares in July 2020. Additionally, the Company must pay royalty payments, in cash, to NLT equal to declining (over time) percentages of the Company’s future net sales of certain of the acquired product technologies not to exceed $43.0 million in the aggregate. The Company has the option to terminate any future obligation to make royalty payments by making a one-time cash payment to NLT of $18.0 million.
Contingent consideration liabilities are classified within Level 3 of the fair value hierarchy because they use significant unobservable inputs. For those liabilities, fair value is determined using a probability-weighted discounted cash flow model and significant inputs which are not observable in the market. The significant inputs include assumptions related to the timing and probability of the product launch dates, estimated future sales of the products, estimated commission rates, discount rates matched to the timing of payments, and probability of success rates.
The following table sets forth the changes in the estimated fair value of the Company’s liabilities measured on a recurring basis using significant unobservable inputs (Level 3). The loss from change in fair value of contingent milestone and royalty payments resulted from updated estimated timing of payments, probability of success rates, the passage of time, updated discount rates matched to the estimated timing of payments, actual net sales of certain products for the three and six months ended June 30, 2020, and estimated net sales for future royalty payment periods.
A change in estimated timing of payments, probability of success rates, or estimated net sales for future royalty payment periods would be expected to have a material impact on the fair value of contingent milestone and royalty payments.

17

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Three Months Ended June 30, 2020:
 
(in thousands)

Balance as of March 31, 2020
 
$
2,045

    Contingent consideration liabilities settled
 
(39
)
Loss from change in fair value of contingent consideration recorded in general and administrative expenses
 
100

Fair value at June 30, 2020
 
$
2,106

Six Months Ended June 30, 2020:
 
(in thousands)

Balance as of January 1, 2020
 
$
2,094

    Contingent consideration liabilities settled
 
(72
)
Loss from change in fair value of contingent consideration recorded in general and administrative expenses
 
84

Fair value at June 30, 2020
 
$
2,106




18

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

9. EQUITY AND STOCK-BASED COMPENSATION
Common Stock
In January 2020, the Company entered into an Underwriting Agreement with Piper Sandler & Co. and Canaccord Genuity LLC relating to the issuance and sale of 6,800,000 shares of the Company’s common stock at a price to the public of $12.50 per share, before underwriting discounts and commissions. Under the terms of that agreement, the Company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 1,020,000 shares of common stock. The underwriters exercised this option and the offering closed on January 10, 2020 with the sale of 7,820,000 shares of common stock, resulting in net proceeds to the Company of approximately $91.6 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The offering was made pursuant to the Company’s shelf registration statement on Form S-3 that was declared effective on May 22, 2019.
Equity Award Plans
As of June 30, 2015, Integra had stock options, restricted stock awards, performance stock awards, contract stock awards and restricted stock units outstanding under three plans, the 2000 Equity Incentive Plan, the 2001 Equity Incentive Plan, and the 2003 Equity Incentive Plan. In connection with the spin-off, Integra equity awards granted to individuals who became employees of SeaSpine were converted to equity awards denominated in SeaSpine common stock. In general, each post-conversion award is subject to the same terms and conditions as were applicable to the pre-conversion award.
In May 2015, the Company adopted the 2015 Incentive Award Plan, which was subsequently amended and restated with approval of the Company's stockholders. In February and March 2018, the Company's board of directors approved amendments to the plan that increased the share reserve by an aggregate of 2,726,000 shares over the then-existing share reserve thereunder, subject to stockholder approval. The Company's stockholders approved both amendments in May 2018. On April 13, 2020, the Company's board of directors approved an amendment to the plan that, among other things, increased the share reserve by an aggregate of 3,500,000 shares over the then-existing share reserve thereunder, subject to stockholder approval. The Company's stockholders approved the amendment on June 3, 2020 (the 2015 Incentive Award Plan, as amended and restated to date, the Restated Plan). Under the Restated Plan, the Company can grant its employees, non-employee directors and consultants incentive stock options and non-qualified stock options, restricted stock, performance stock, dividend equivalent rights, stock appreciation rights, stock payment awards and other incentive awards. The aggregate number of shares that may be issued or transferred pursuant to awards under the Restated Plan is the sum of (1) the number of shares issuable upon exercise or vesting of the number of Integra equity awards converted to the Company's equity awards under the Restated Plan as of the date of the spin-off and (2) 9,735,500 shares of its common stock in respect of awards granted under the Restated Plan. As of June 30, 2020, 3,931,226 shares were available for issuance under the Restated Plan.
In June 2018, the Company established the 2018 Employment Inducement Incentive Award Plan (the 2018 Inducement Plan). The terms of the 2018 Inducement Plan are substantially similar to the terms of the Restated Plan with these principal exceptions: (1) incentive stock options may not be granted under the 2018 Inducement Plan; (2) there are no annual limits on awards that may be issued to an individual under the 2018 Inducement Plan; (3) awards granted under the 2018 Inducement Plan are not required to be subject to any minimum vesting period; and (4) awards may be granted under the 2018 Inducement Plan only to those individuals and in those circumstances described below. An aggregate of 2,000,000 shares are reserved under the 2018 Inducement Plan. As of June 30, 2020, 1,908,483 shares were available for issuance under the 2018 Inducement Plan. As a result of the approval of the amendment to the Restated Plan by the Company's stockholders in June 2020, no awards will be granted under the 2018 Inducement Plan in the future.
The 2018 Inducement Plan was adopted by the Company’s board of directors without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under this plan may only be made to an employee who has not previously been an employee or member of the Company's board of directors or of any board of directors of any parent or subsidiary of the Company, or following a bona fide period of non-employment by the Company or a parent or subsidiary, if he or she is granted such award in connection with his or her commencement of employment with the Company or a subsidiary and such grant is an inducement material to his or her entering into employment with the Company or such subsidiary.
Forfeiture Rate Assumptions
Stock-based compensation expense related to all equity awards includes an estimate for forfeitures. The expected forfeiture rate of all equity-based compensation is based on historical experience of pre-vesting forfeitures on awards and options by each homogeneous group of shareowners. For awards and options granted to non-executive employees, the forfeiture rate is estimated to be 14% annually for the six months ended June 30, 2020 and 13% annually for the six months ended June 30,

19

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

2019. There is no forfeiture rate applied to awards or options granted to non-employee directors or executive employees because their pre-vesting forfeitures are anticipated to be highly unlikely. As individual awards and options become fully vested, stock-based compensation expense is adjusted to recognize actual forfeitures.
Restricted Stock Awards and Restricted Stock Units
Restricted stock award and restricted stock unit grants to employees generally have a requisite service period of three years, and restricted stock award and restricted stock unit grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company expenses the fair value of restricted stock awards and restricted stock units on an accelerated basis over the vesting period or requisite service period, whichever is shorter.
During each of the three and six months ended June 30, 2020, there were 72,520 shares of restricted stock awards granted to non-employee directors. During the three and six months ended June 30, 2019, there were 64,631 and 76,471 shares of restricted stock awards granted to non-employee directors, respectively. No restricted stock units were granted to non-employee directors during the three or six months ended June 30, 2020 or 2019.
During the three and six months ended June 30, 2020, 30,267 and 376,754 restricted stock units were granted to employees, respectively. During the three and six months ended June 30, 2019, there were 7,800 and 218,610 restricted stock units granted to employees, respectively. No restricted stock awards were granted to employees during the three or six months ended June 30, 2020 or 2019.
As of June 30, 2020, there was approximately $5.0 million of unrecognized compensation expense related to the unvested portions of restricted stock awards and of restricted stock units. This expense is expected to be recognized over a weighted-average period of approximately 1.1 years.
Stock Options
Stock option grants to employees generally have a requisite service period of four years, and stock option grants to non-employee directors generally have a requisite service period of one year. Both are subject to graded vesting. The Company records stock-based compensation expense associated with stock options on an accelerated basis over the applicable vesting period within each grant and based on their fair value at the date of grant using the Black-Scholes-Merton option pricing model. There were 238,491 and zero stock options granted during the three months ended June 30, 2020 and 2019, respectively, and 920,250 and 434,708 stock options granted during the six months ended June 30, 2020 and 2019, respectively. The following weighted-average assumptions were used in the calculation of fair value for options granted during the period indicated.
 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
 
2020
 
2019
 
2020
 
2019
Expected dividend yield
 
%
 
%
 
%
 
%
Risk-free interest rate
 
0.2
%
 
2.5
%
 
1.2
%
 
2.5
%
Expected volatility
 
53.6
%
 
30.3
%
 
41.3
%
 
30.3
%
Expected term (in years)
 
2.5

 
2.9

 
2.6

 
2.9


The Company considered that it has never paid, and does not currently intend to pay, cash dividends. The risk-free interest rates are derived from the U.S. Treasury yield curve in effect on the date of grant for instruments with a remaining term similar to the expected term of the options. The expected volatility is calculated based upon the historical volatility of the Company's share prices. The expected term is calculated using the historical weighted average term of the Company’s options.
As of June 30, 2020, there was approximately $2.2 million of unrecognized compensation expense related to unvested stock options. This expense is expected to be recognized over a weighted-average period of approximately 1.6 years.

20

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

Employee Stock Purchase Plan
In May 2015, the Company adopted the SeaSpine Holdings Corporation 2015 Employee Stock Purchase Plan, which was amended in November 2018, as described below (as amended, the ESPP). Under the ESPP, eligible employees may purchase shares of the Company’s common stock through payroll deductions of up to 15% of eligible compensation during an offering period. Generally, each offering period will be for 24 months as determined by the Company's board of directors. There are four six-month purchase periods in each offering period for contributions to be made and to be converted into shares at the end of the purchase period. In no event may an employee purchase more than 2,500 shares per purchase period based on the closing price on the first trading date of an offering period or more than $25,000 worth of stock during any calendar year. The purchase price for shares to be purchased under the ESPP is 85% of the lesser of the market price of the Company's common stock on the first trading date of an offering period or on any purchase date during an offering period (June 30 or December 31).
Subject to stockholder approval, on and effective as of November 2, 2018, the Company's board of directors approved an amendment to the ESPP pursuant to which the share reserve under the ESPP would increase from 400,000 shares to 800,000 shares. The Company's stockholders approved that amendment in May 2019. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Internal Revenue Code of 1986, as amended (the IRC). The ESPP contains a restart feature, such that if the market price of the stock at the end of any six-month purchase period is lower than the market price at the original grant date of an offering period, that offering period will terminate after that purchase date, and a new two-year offering period will commence on the January 1 or July 1 immediately following the date the original offering period terminated. This restart feature was triggered on the purchase date that occurred on June 30, 2019, such that the offering period that commenced on January 1, 2019 was terminated, and a new two-year offering period commenced on July 1, 2019 and would end on June 30, 2021. This restart feature was triggered again on the purchase date that occurred on December 31, 2019, such that the offering periods that commenced on each of July 1, 2018 and July 1, 2019 were terminated, and a new two-year offering period commenced on January 1, 2020 and would end on December 31, 2021. This restart feature was triggered again on the purchase date that occurred on June 30, 2020, such that the offering period that commenced on January 1, 2020 was terminated, and a new two-year offering period commenced on July 1, 2020 and will end on June 30, 2022. The Company applied share-based payment modification accounting to the awards that were initially valued at the grant date to determine the amount of any incremental fair value associated with the modified awards. The impact to stock-based compensation expense for modifications during the six months ended June 30, 2020 was immaterial.
During the six months ended June 30, 2020 and 2019, there were 78,360 and 64,008 shares of common stock, respectively, purchased under the ESPP. The Company recognized $0.4 million in expense related to the ESPP for each of the six months ended June 30, 2020 and 2019. As of June 30, 2020, 202,102 shares were available under the ESPP for future issuance.
The Company estimates the fair value of shares issued to employees under the ESPP using the Black-Scholes-Merton option-pricing model. The following weighted average assumptions were used in the calculation of fair value of shares under the ESPP at the grant date for the periods indicated:
 
Three and Six Months Ended June 30,
 
2020
 
2019
Expected dividend yield
%
 
%
Risk-free interest rate
1.6
%
 
2.5
%
Expected volatility
34.4
%
 
39.0
%
Expected term (in years)
1.2

 
1.2



21

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

10. LEASES
The impact of the adoption of Topic 842 to the Company's applicable balance sheet items as of January 1, 2020 is presented in the table below. The standard did not have a material impact to the Company's unaudited condensed consolidated statements of operations or comprehensive loss or cash flows.
(in thousands)
December 31, 2019
 
Impact of Adoption of ASC 842
 
January 1, 2020
ASSETS
 
 
 
 
 
Right of use assets
$

 
$
9,059

 
$
9,059

Total assets
$
141,718

 
$
9,059

 
$
150,777

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
 
 
Current liabilities:
 
 
 
 
 
Other accrued expenses and current liabilities
5,444

 
(138
)
 
5,306

Current portion of operating lease liabilities

 
2,080

 
2,080

  Total current liabilities
30,478

 
1,942

 
32,420

Operating lease liabilities, net of current portion

 
8,367

 
8,367

Other liabilities
1,480

 
(1,250
)
 
230

Total liabilities
$
31,958

 
$
9,059

 
$
41,017

Total stockholders' equity
$
109,760

 
$

 
$
109,760

Total liabilities and stockholders' equity
$
141,718

 
$
9,059

 
$
150,777


The Company determines if an arrangement is a lease at inception. The Company's leases primarily relate to administrative, manufacturing, research, and distribution facilities and various manufacturing, office and transportation equipment. Lease assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit rate, the Company's incremental borrowing rate is used as a discount rate, based on the information available at the commencement date, in determining the present value of lease payments. Lease assets also include the impact of any prepayments made and are reduced by impact of any lease incentives.
The Company made an accounting policy election for short-term leases, such that the Company will not recognize a lease liability or lease asset on its balance sheet for leases with a lease term of twelve months or less as of the commencement date. Rather, any short-term lease payments will be recognized as an expense on a straight-line basis over the lease term. The current period short-term lease expense reasonably reflects the Company's short-term lease commitments.
The Company made a policy election for all classifications of leases to combine lease and non-lease components and to account for them as a single lease component. Variable lease payments are excluded from the lease liability and recognized in the period in which the obligation is incurred. Additionally, lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise the option.
The Company’s lease portfolio only includes operating leases. As of June 30, 2020, the weighted average remaining lease term of these operating leases was 5.7 years and the weighted average discount rate was 6.5%. For the three and six months ended June 30, 2020, lease expense, which represents expense from operating leases, was $0.6 million and $1.1 million, respectively.

22

SEASPINE HOLDINGS CORPORATION
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (continued)

A summary of the Company's remaining lease liabilities at June 30, 2020 are as follows:
 
Operating Leases

 
(In thousands)

2020
1,894

2021
3,340

2022
2,238

2023
1,563

2024
1,369

Thereafter
3,273

Total undiscounted value of lease liabilities
$
13,677

Less: present value adjustment
(2,052
)
Less: short-term leases not capitalized
(1,964
)
Present value of lease liabilities
9,661

Less: current portion of lease liability
(2,110
)
Operating lease liability, less current portion
$
7,551


11. INCOME TAXES
The following table summarizes the Company’s effective tax rate for the periods indicated: 
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2020
 
2019
 
2020
 
2019
 
 
 
 
 
 
 
 
Reported income tax expense rate
(0.2
)%
 
(0.2
)%
 
(0.3
)%
 
(0.2
)%

The Company recorded a provision for income tax expense for the three and six months ended June 30, 2020 primarily related to foreign and state operations.
In addition, for all periods presented, the pretax losses incurred by the consolidated U.S. tax group received no corresponding tax benefit because the Company concluded that it is more likely than not that the Company will be unable to realize the value of any resu